|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Service des Maladies du Sang, Centre
Hospitalo-Universitaire, Angers, France; and Centre J. Bernard, Le
Mans, France.
At diagnosis, approximately 80% of patients with
follicular lymphoma (FL) have disseminated disease with one or more
extranodal localizations (Ann Arbor stage IV), mostly corresponding to
bone marrow (BM) involvement. Conventional chemotherapy is not curative nor does it substantially modify the natural course of the disease. Most patients with disseminated FL ultimately die from the disease, with a median survival time of 8 to 10 years.1 Innovative
therapies have to be proposed to these patients. Some form of intensive therapy Clinical results
Progressing or relapsing patients.
Johnson et al2 have clearly shown that, after each
subsequent relapse of FL, the response rate to treatment decreases and the progression-free survival (PFS) time shortens (Table
1). This explains why most intensive
therapies have been performed in patients with disseminated disease who
have either not responded to initial conventional treatment or relapsed
after one or more regimens of chemotherapy. The data from several
retrospective series of ASCT in progressing/relapsing FL patients have
been published. The main reports are summarized in Table
2.3-17 They all indicate
encouraging results, with a response rate higher than 90%, low
(5%-10%) TRM, and long median relapse-free survival (RFS) and overall
survival (OS) times. Nevertheless, most patients still relapse after
ASCT, and cure has not been demonstrated. Besides, conclusions are
difficult to draw on the basis of these reports because of the presence
of one or more skewing factors, including different classifications of
low-grade lymphomas, patients with and without histological
transformation, the selection of patients who were suitable for ASCT,
differences in conditioning regimens, the use of BM or peripheral blood
stem cells, reinjection of purged or unpurged stem cells, and short
follow-up periods.
Although these results clearly suggest that intensive therapy is probably superior to conventional chemotherapy in relapsing FL patients, only a randomized trial could confirm this hypothesis. Such a trial was launched in Europe for chemotherapy unpurged bone marrow or purged bone marrow (the CUP trial) but was stopped because of poor patient recruitment (89 randomized patients in 4 years). The trial showed a significant improvement in the progression/relapse rate in the ASCT group (44% in the chemotherapy arm as opposed to 32% in the intensive arm, P = .006) without any difference in OS.18 Several prognostic factors that significantly influenced PFS and/or OS after ASCT have been described: (1) age (with a threshold around 50 years)13; (2) B symptoms at diagnosis and/or on relapse6,19 and/or increased serum lactate dehydrogenase (LDH) levels20; (3) number of previous chemotherapy regimens11,13,21; (4) clinical status at the time of ASCT (patients who have resistant disease are less likely to benefit from ASCT than those with chemosensitive disease)4,11,13,20; (5) presence or absence of histological transformation (several groups have reported on small numbers of patients with histologically transformed FL treated with HDT).11,15,22-27 In the first report of high-risk patients with histologically transformed FL, poor performance status, and bulky or chemoresistant disease, the results were poor with only 1 patient of 10 still surviving one year after HDT.22 More recent series have reported better results (Table 3).11,15,23,24,27 The European Bone Marrow Transplantation (EBMT) registry reported on 50 patients treated with HDT for histologically transformed FL.25 Median PFS after HDT was 13 months, and OS was 64% and 51% at 2 and 5 years, respectively. Results of HDT performed after histological transformation were not different from those of 200 matched, untransformed FL and 200 de novo cases of aggressive non-Hodgkin lymphoma (NHL) treated with HDT (P = .67 and .44).25 These results can be considered as better than those reported for patients treated with conventional chemotherapy.28 However, results of HDT in histologically transformed FL are too limited to allow any firm conclusions to be drawn.); (6) histological BM involvement at the time of stem cell harvest6; (7) the bcl-2-JH polymerase chain reaction (PCR) graft status after the purge procedure, if any was performed. The influence of a negative PCR bcl-2-JH rearrangement has been clearly demonstrated by retrospective analysis of patients who were treated with ABMT at the DFCI. PCR detected residual disease at the time of marrow stem cell harvest in 113 of 153 patients. After immunologically purged ABMT, BM PCR analysis showed no detectable disease in 48 patients (42%), whereas 65 (58%) remained PCR positive. Patients whose BM was negative for the bcl-2-JH rearrangement after purged ABMT experienced longer freedom from relapse (FFR) than those whose BM remained positive [6 of 48 relapses versus 49 of 65, and 8-year FFRs of 83% vs 19%, respectively, P < .001].)6; and, finally, (8) residual disease after ASCT. In the DFCI study, continued bcl-2-JH PCR negativity in blood or BM during follow-up was also strongly predictive of prolonged complete remission (CR) after ABMT (5 relapses among the 47 patients with persistently negative samples during follow-up compared to 36 of 39 relapses in patients with positive PCR in all BM samples after ABMT). PCR positivity after purging and in BM samples after transplantation were the only parameters associated with a poorer FFR after ABMT in a univariate analysis (P < .0001).6 Some studies have confirmed the prognostic influence of a negative bcl-2-JH PCR result after ASCT,29-31 but others showed a similar relapse rate whatever the PCR status.32 Real-time quantitative PCR evaluations that provide an accurate and reproducible estimate of the number of gene copies with a low carry-over contamination risk could account for these discrepancies.33 Using this technique as well as limiting dilution assays combined with 2-step PCR, relapses among 15 patients were associated with increasing numbers of circulating t(14;18)-positive cells and continuous CR with stable cell counts.34 For patients without any detectable chromosomal rearrangement, amplification of the third complementary determining region (CDR III) can be useful as a clonal marker for minimal residual disease.35 No relapse occurred in any of the 10 patients in whom HDT eradicated PCR-detectable lymphoma cells with this technique, whereas all 8 patients with PCR-detectable lymphoma cells after ABMT relapsed (P = .0002).35
ASCT as first-line therapy.
A few Phase II trials of intensive therapy after maximum response to
conventional chemotherapy have been reported in FL
patients.4,16,37-44 The results are summarized in Table
4. In a nonrandomized comparison of 26 patients treated with a high-dose CHOP-like regimen (cyclophosphamide, vincristine, prednisone, and doxorubicin) followed by ABMT,
and 14 patients treated with the same regimen without ABMT, there was a
significant improvement in DFS in the ABMT group (a DFS of 54% at 36 months in the group treated with ABMT versus 26% in the group treated
with conventional chemotherapy) without any difference in
OS.38 Horning et al have compared the survival of 37 patients treated with ABMT after a maximum response to conventional chemotherapy and 61 matched historical controls in CR or unconfirmed CR
after conventional chemotherapy. With a median follow-up of 6.5 years,
the estimated 10-year survival rate was 86% in the transplantation
group and 59% in the conventional chemotherapy group
(P = .074).39 Recently, Sanz-Rodriguez et
al45 has reported on a retrospective comparison of a group
of patients initially treated with ASCT and a group of matched controls
treated with a conventional treatment (cyclophosphamide, vincristine,
and prednisone [CVP] chemotherapy associated with interferon alpha).
With a median follow-up of 87 months and 112 months, respectively,
there was no difference in PFS (49.5% and 48%, respectively) or OS
(76% and 71%).45 In another nonrandomized comparison,
when survival was calculated from the date of diagnosis, there was no
difference in event-free survival and OS between a group of 33 patients
treated with ASCT at the outset and a group of 22 patients treated with ASCT only on relapse.16
Optimal procedure Collection and purging of stem cells. Autologous peripheral blood stem cell transplantation (APBSCT) has progressively replaced ABMT since retrospective analyses49,50 and at least 3 randomized studies51-53 demonstrated that the time taken for neutrophils or platelet recovery, the duration of the hospital stay, the incidence of infectious complications, and the overall cost are less after APBSCT than after ABMT. Besides, the rate of contamination by lymphoma cells is similar with both harvest procedures,54,55 and posttransplantation PFS and OS rates are similar.50 Finally, immune reconstitution is faster after APBSCT than after ABMT.56 Leukapheresis for peripheral blood stem cell collection may be performed after either conventional chemotherapy followed by granulocyte colony-stimulating factor (G-CSF) treatment57 or G-CSF treatment alone.58,59 In a nonrandomized comparison between these 2 procedures, there were no differences in transplantation outcome (stem-cell engraftment, risk of relapse).60,61 A combination of stem cell factor (SCF) and G-CSF resulted in the collection of a higher number of stem cells62,63 and has to be more extensively evaluated in patients in whom the harvest is insufficient after chemotherapy plus G-CSF or G-CSF alone.64,65 Several factors influence the number of stem cells that can be collected, including BM involvement,66 the number of previous chemotherapy regimens,66-71 the time interval between collection and the last cycle of chemotherapy,68,72 previous treatments with radiation and/or cytotoxic drugs (especially the total cumulative dose of alkylating agents66), and fludarabine treatment in some series.73-75 In general, stem cell collections are poorer and the rate of failure to collect a sufficient number of CD34+ stem cells to perform ASCT is greater in low-grade lymphomas than in aggressive lymphomas. The reasons for this are not understood.68 Lymphoma cells often contaminate BM69,76,77 and peripheral blood54 stem cell collections and may contribute to relapse after ASCT.78,79 Thus, purging collected stem cells ought to help decrease contamination and lower the risk of relapse. Several procedures have been proposed to purge BM and/or peripheral blood stem cells. (1) In vitro treatment with cytotoxic agents (4-hydroperoxycyclophosphamide or mafosfamide) has deleterious effects on normal hematopoietic stem cells.19 (2) In vitro treatment with a cocktail of anti-B-cell monoclonal antibodies (anti-CD20, anti-CD10, and anti-CD19) and fresh rabbit complement,80 or passing the blood81 or BM stem cells82 over a column containing anti-B-cell antibodies bound to immunomagnetic beads. This procedure significantly decreases the number of lymphoma cells in a BM graft as assessed by PCR amplification of the bcl-2-JH rearrangement.83 In the DFCI study, 57 of 114 (50%) patients with PCR-positive BM became negative after purging.80 However, in another study, 18 of 21 (86%) patients remained positive after treatment with a cocktail of 4 monoclonal antibodies.84 (3) In vitro positive selection of CD34+ hematopoietic stem cells,85,86 which produces a 3- to 4-log reduction in tumor contamination.86,87 Although hematopoietic recovery is not delayed88 after ASCT with CD34-selected stem cells, slow T- and B-cell recovery may increase the risk of opportunistic infections.89,90 Nevertheless, CD34-selected grafts may remain contaminated with lymphoma cells.69,91 (4) Selection of the CD34+CD19 subpopulation
that is less contaminated than the CD34+
fraction.91 However, even a
CD34+CD19CD20 stem cell
population may contain the bcl-2-JH rearrangement.92,93
(5) Ex vivo expansion of the hematopoietic stem cells using a
combination of growth factors such as SCF, interleukin 3, interleukin 6, G-CSF, and Flt-3 ligand that accelerates hematological
reconstitution after HDT.94,95 This ex vivo expansion of
bcl-2-JH-negative CD34+ progenitor cells does not induce
the expansion of lymphoma progenitor cells,93,96 but the
data are scarce and need confirmation.
(6) More recently, an in vivo purging method has been proposed using a
treatment with rituximab before stem cell collection.97,98 The results of the first studies are encouraging. When rituximab is
combined with chemotherapy, lymphoma cells became undetectable in
peripheral blood stem cell collections in 75% (9 of
12),99 93% (14 of 15),97 or 100% (7 of
7)98 of informative cases, a significantly higher rate than
in historical control (26%98 to 40%97).
However, a single rituximab infusion 3 to 5 days before stem cell
collection is insufficient since 10 of 11 stem cell grafts remained
PCR-positive.100 Anti-CD20 monoclonal antibody in vivo
purging does not have a deleterious effect on stem cell collection,
engraftment time, or transplantation outcome.101,102 A
trial conducted by the European Bone Marrow Transplantation group is
currently assessing the role of rituximab in ASCT for relapsing FL in a
4-arm randomized trial, rituximab being (1) not given in a control
group; (2) given before stem cell collection; (3) given after ASCT; and
(4) given before collection and after ASCT.
The clinical benefit of the purge procedure remains to be established.
After a reduction of lymphoma cell numbers to below a threshold level
of 1 lymphoma cell of 104 to 105 mononucleated
cells, the risk of relapse is decreased in some studies5,6,76 but is similar to the relapse rate after
unpurged ASCT in other retrospective analyses32,103 or in a
comparison of registry data.25 Only a randomized study
could confirm the role of purging. One such trial has been initiated
but was stopped because of poor patient recruitment (the CUP
trial),18 and it is unfortunately unrealistic to undertake
another trial comparing ASCT with or without purging of the stem cell
graft. In vitro purging is an expensive and cumbersome technique.
Treatment before stem cell collection with rituximab or another
anti-B-cell antibody such as humanized anti-CD22 (hLL2)104
is more promising, given that it is both an anti-lymphoma treatment and
an in vivo purging procedure. Confirmatory data are needed.
Conditioning regimens. Schematically there are 2 types of conditioning regimens for ASCT: (1) those based on chemotherapy alone, such as CBV (cyclophosphamide, carmustine, etoposide),105 BEAM (carmustine, etoposide, cytarabine, melphalan),13 or BEAC (carmustine, etoposide, cytarabine, cyclophosphamide)7; and (2) those using a chemoradiotherapy combination with total body irradiation (TBI).5,6 The efficacy of very low-dose TBI (1.0 to 2.0 Gy in 0.25 to 0.50 Gy fractions) was demonstrated in low-grade NHLs some 25 years ago.106 Usually, TBI as a conditioning regimen before ASCT is administered in 6 fractions of 2 Gy each (fractionated TBI) rather than as a single dose of 12 Gy, which is more toxic.107 TBI is usually combined with high-dose cyclophosphamide5,6 and, in some studies, VP16.3,108 There is no randomized study comparing conditioning regimens in FL. Several retrospective comparisons have been reported, but the results are conflicting. Some report better overall survival with chemotherapy alone,109 whereas the opposite was found in others with better OS when fractionated TBI was used.15 In some studies, no difference was observed.16,110 Treatment with a murine anti-CD20 monoclonal antibody coupled with a high dose of 131I may be an interesting alternative, given that it allows delivery of a significantly higher dose of radiation to the tumor without too much damage to normal organs. The results of a preliminary phase I-II trial where this high-dose radioimmunotherapy was combined with cyclophosphamide and VP16 were promising. Doses up to 75 Gy could be delivered to affected sites without exceeding doses of 20 Gy to the lungs or other radiosensitive organs.111 However, such a conditioning regimen can be given only in a limited number of centers. Other Phase I-II trials using high-dose radioimmunotherapy with humanized anti-CD20 and anti-CD22 MoAbs are in progress.112Treatments after ASCT As previously mentioned, residual disease is often present after ASCT and may contribute to relapse.29,113 Several post-ASCT adjuvant treatment modalities have been tested to eradicate residual disease and decrease the relapse rate.114,115MoAbs conjugated to toxins such as the anti-B-cell immunotoxin anti-B4-blocked ricin have proven disappointing as an adjunctive therapeutic modality after ABMT.116 Rituximab used as an adjunctive immunotherapy after PBSCT is well tolerated but can induce transient neutropenia100,102 or delayed immune reconstitution, although without any increase in infectious complications.117 However, the ultimate determination of its efficacy will require the results of ongoing studies. Immune-mediated antitumor therapy after ASCT has been recently reviewed in Blood.111 (1) Cytokines may be of therapeutic value as their endogenous production is decreased after ASCT,118,119 and their administration soon after ASCT120 can activate cytotoxic T cells directed against lymphoma cell antigens.121-123 A phase II trial of rIL-2 (3 to 6 IU/m2/d × 5 d/wk for 4 weeks) combined with interferon (IFN) alpha (3 × 106 U/d × 5 d/wk) given after hematological recovery in relapsing lymphoma patients treated with ABMT has shown a significant improvement in survival when compared to historical controls without post-ABMT immunotherapy (4-year survival of 90% vs 46%) and resulted in a significant decrease in relapse rate (20% vs 46%).124 However, the hematological and systemic toxicities of IL-2 restrict its usefulness after ASCT. (2) Cyclosporine A (CyA), which prevents the thymic clonal deletion of
autoreactive T lymphocytes, can increase the incidence of autologous
graft-versus-host disease (GVHD),125 a syndrome similar to
allogeneic cutaneous GVHD, which is observed in 5% to 10% of
patients.126 Encouraging results have been reported in a
phase II trial of CyA (in combination with (3) An anti-idiotype immune reaction may be induced by infusions of specific idiotypes coupled with a potent adjuvant128-130 such as granulocyte-macrophage colony-stimulating factor (GM-CSF),131 the C fragment of tetanus toxin,132 or ex vivo-pulsed dendritic cells that act as antigen-presenting cells133,134 and considerably increase the immune response to idiotype proteins. About 50% of patients develop a cellular and/or an antibody-mediated anti-idiotypic reaction, and in these patients the risk of relapse after ASCT is significantly decreased.130,135,136 Tumor vaccination can be performed either after ASCT with minimal residual disease, or before stem cell harvest, which prevents posttransplantation immunosuppression. Using a syngeneic murine bone marrow transplantation (BMT) model, the tumor-free survival rate was greater after vaccination with irradiated GM-CSF-producing autologous tumor cells in the post-BMT period than in the nontransplantation context.137 Evaluating the potential clinical benefits of these modalities requires further studies. Complications after ASCT Relapse. Relapses after ASCT often occur in sites of previous disease (78% among 33 patients who relapsed after ABMT for FL).138 In some retrospective analyses, posttransplantion radiation therapy improved event-free survival when compared to historical controls.19 Relapses after ASCT often have the same pathological aspects as before intensive therapy,138 but patients may relapse either with histological transformation138 or, conversely, after ASCT for transformed FL with a low-grade FL ("down-staging").24 Relapses after ASCT tend to respond to conventional chemotherapy138 and/or to monoclonal anti-CD 20 antibodies.139,140Myelodysplastic syndromes/acute leukemias and other secondary tumors. Myelodysplastic syndrome and acute leukemia (MDS/AL) are the major long-term complications of ASCT for FL.21,141-145 Their 5-year incidence for NHL following ASCT has been estimated to be 8% to 14%5,144-146 and may be higher in low-grade as opposed to aggressive NHL.147 The prognosis is very poor, with a median survival of 9.4 months.148 Some factors may increase the risk of MDS/AL, such as advanced age,142,144,149 prior fludarabine therapy,150 the total cumulative dose of alkylating agents,141 radiation therapy before ASCT,148,149,151 the use of TBI in the conditioning regimens142,144,149 or stem cell priming with high-dose VP-16,151 the use of peripheral blood stem cell (PBSC) rather than BM progenitors,144 or the median number of cells/kg reinfused.148 Cytogenetic BM analysis before ABMT may allow prediction of the risk of MDS/AL.149,152 The incidence of acquired karyotypic instability observed during serial assessment after ASCT may greatly exceed the clinical incidence of MDS/AL (13 instances of karyotypic instability versus 2 cases of MDS/AL in a total of 22 patients).153
When the follow-up time is prolonged, the pattern of relapses after ASCT appears as continuous, without any plateau. Moreover, ASCT is not feasible when the marrow reserves are inadequate, and it is poorly effective for patients with refractory disease or extensive BM involvement. In such situations, the curative value of allogeneic SCT can now be assessed by analyzing a greater amount of information. Clinical results An analysis of 215 patients reported on in 8 different studies,9,10,154-160 including an observational study of 113 patients collected from 50 centers participating in the International Bone Marrow Transplant Registry (IBMTR),155 is summarized in Table 5. From these results, it appears that standard allogeneic BMT was offered mainly to patients with advanced, chemotherapy-resistant disease with extensive BM involvement and after extensive prior therapy in most cases. In these conditions, a high TRM (around 40%) is counterbalanced by the very potent antitumoral effect of allogeneic BMT, allowing high lymphoma-free and OS rates (49% to 80%) due to a low recurrence rate (0% to 20%).10,154-157,159 Indeed, if the registry follow-up method is accurate, only 1 relapse occurred among 33 patients monitored for more than 2 years.155 Interestingly, and in contrast to the outcome with many other malignancies, a full response and long-term disease-free survival have been observed even in patients with refractory disease.10,154,158,161 These data indicate that patients with refractory or recurrent low-grade lymphoma have a better chance of cure when they are treated with allogeneic BMT than when they are treated with ASCT. However, in the IBMTR study, a higher survival rate was associated with good pretransplantation performance status, chemotherapy-sensitive disease, use of a TBI-containing conditioning regimen, and age younger than 40 years.155 Better patient selection and earlier transplantation could improve outcomes.159,162 In one study, patients with sensitive disease not heavily treated have a low TRM rate (14% vs 86% in patients with resistant disease).162 In contrast to ASCT, the long-term pattern of which does not reach a plateau, allogeneic SCT has a curative potential as witnessed by the fact that long-term remission (as determined by molecular analysis) was observed in 3 of 7 evaluable patients.163
Graft-versus-lymphoma effect The lower relapse rate after allogeneic BMT compared with autologous BMT is likely due to the lack of BM contamination of the graft and to an immune-mediated graft-versus-lymphoma (GvL) effect. Evidence of a GvL effect come from 2 things.It can come from the response to persistent disease following allogeneic BMT, which is observed at the same time as the development of active acute or chronic GVHD. In an EBMT retrospective study, a lower recurrence rate was found in patients with chronic GVHD compared with those without GVHD (0% vs 35%, P = .02),164 although this relationship is still controversial.155 However, the incidence of GVHD in FL seems to be remarkably high (Table 4) compared with that in leukemia patients, probably because FL recipients and donors tend to be older.156 Evidence of a GvL effect also comes from induction of remission after cessation of immunosuppression or donor-leukocyte infusion (DLI).156,165 Quantification of the disease activity by real-time PCR with an internal fluorogenic probe for the t(14;18) translocation has been used to investigate the GvL effect of donor leukocytes given for relapsed follicular NHL after allogeneic BMT.166 Cytoreduction after DLI may take several months to occur.154,159 So, the better outcome after allogeneic BMT in patients with FL compared to that in patients with high-grade subtypes may be explained not only by the more indolent course of the disease and the better condition of patients, but also by the GvL effect. Optimal procedure Modalities to reduce the toxicity of the conditioning regimen and the risk of GVHD and to separate the latter from the beneficial GvL effect are required.Conditioning regimens. The high response rate after allogeneic or autologous BMT is due at least in part to the intensive conditioning regimen. Several attempts have been made to improve the efficiency and decrease the toxicity of such regimens, but no randomized data are available to assess their respective value. In the IBMTR survey, a higher survival rate was associated with the use of a TBI-containing conditioning regimen. However, only 18% of these patients received non-TBI regimens, and it is possible that unknown factors may have skewed the results.155 An increase in the intensity of the conditioning regimen in 15 patients was associated with an increase in severe acute GVHD despite T-cell depletion of the graft, probably due to supplementary impairment of the recipient's immune status.156 Source of allogeneic hematopoietic stem cells. Apheresis products containing G-CSF-mobilized peripheral blood cells can be safely obtained from allogeneic donors. Seven recently reviewed167 randomized trials in various hematological neoplasias have demonstrated that neutrophil and platelet recovery and immune reconstitution were faster with peripheral blood cells than with marrow.168 The risk of acute GVHD is not increased, even though the number of T cells in the blood is 10-fold higher than that in the BM. Moreover, in 2 of these studies, the incidence of chronic GVHD was higher among patients who received peripheral blood cells. This procedure may offer advantages in terms of OS and DFS, especially in patients with high risk of relapse. GVHD prophylaxis. The incidence of acute and chronic GVHD following allogeneic BMT can be reduced by several modalities. (1) T-cell depletion. T-cell depletion, performed in vitro by elutriation or monoclonal antibodies or in vivo by the addition of CAMPATH-1G, may decrease the high TRM rate (4.5% of 22 patients treated with alloBMT for relapsed indolent lymphoma at the DFCI).160,169 Conversely, it may increase graft failure (10%), delay engraftment, mixed chimerism, disease recurrence, and Epstein-Barr virus-associated lymphoproliferative disorder.10,156 Delayed engraftment secondary to T-cell depletion might be overcome by reinfusion of the fraction of small CD34+ cells that coseparate with the small lymphocytes.170 However, decreasing GVHD inhibited the GvL effect. Thus, after T-cell-depleted allogeneic BMT, 4 of 5 patients with clinical CR and informative PCR for the bcl2/IgH translocation remained PCR-positive after transplantation.171 (2) Delayed administration of small, graded doses of donor lymphocytes172 and the identification and reinjection of specific lymphocyte subtypes.169 For example, CD6+ T-cell-depleted allogeneic BMT resulted in 54% and 59% DFS and OS, respectively, in poor-risk relapsing FL over a median follow-up time of 30 months.169 T-cell-depleted allogeneic BMT followed by donor lymphocyte infusion (DLI) appears to be effective in poor-risk patients with relapsing FL.156 Preliminary results of a randomized trial suggest that CD8 depletion of DLI reduces the incidence of GVHD associated with DLI without compromising antitumor activity, conversion to donor hematopoiesis, or immunologic recovery.173 (3) Transduction of the donor lymphocytes with a suicide gene, such as the herpesvirus thymidine kinase, that confers sensitivity to ganciclovir and allows the effector cells to be eradicated if GVHD occurs.174 (4) Other immunosuppressive agents such as mycophenolate mofetil, FK506, CAMPATH-1, or monoclonal IL-2 receptor are currently being evaluated.Nonmyeloablative preparative regimen. An alternative strategy to reduce TRM and improve the age cutoff is to use a lower dose, nonmyeloablative, preparative regimen designed not to eradicate the malignancy but to provide sufficient immunosuppression to achieve engraftment of an allogeneic graft, thus allowing the development of an immune GvL effect. Results from more than 600 patients with various hematological malignancies have been reported, including 18% with NHL.175-186 Nonmyeloablative preparative regimens contain fludarabine and 200 cGy TBI,175 cyclophosphamide,161 busulfan with181,182 or without176,185 anti-T-lymphocyte globulin, melphalan with184 or without176,183,186 CAMPATH-1H or carmustine.177 Thiotepa-based regimens with fludarabine,180 cyclophosphamide,179 or both178 are also investigated. GVHD prophylaxis consisted in cyclosporine A and methotrexate,176-179 tacrolimus,161,187 or mycophenolate mofetil and175,185 or T-cell depletion.186 If residual malignant cells or mixed chimerism are detected, donor lymphocytes are infused to potentiate the GvL effect. Graft rejection occurred in < 5%, whereas the frequency of mixed chimerism ranged from low175 to 40%184 of patients. TRM occurred in between 10% and 40% of cases. Median granulocyte and platelet nadirs are high, 0.3 and 60 G/L, respectively, in one study,175 and platelet and red blood cell transfusions are significantly decreased.188 Outpatient allografting has even been performed without subsequent hospitalization.189 However, an increased incidence of early viral infection, especially cytomegalovirus (CMV),190 and late gram-negative infection was reported in nonneutropenic patients.191 GVHD remains the major drawback to this procedure and the main cause of death before day 100. The risk for grade III-IV GVHD in those patients whose median age was older than 50 years remains high (10% to 42%). The addition of in vivo CAMPATH-1H to melphalan and fludarabine significantly reduces TRM and the risk of GVHD with marrow transplants from both related and unrelated donors.184 Nonmyeloablative allogenic transplantations are also performed with unrelated donors185,192,193 and in patients who relapsed after autologous BMT.177,178,192,194,195 FL should be a good indication for these nonmyeloablative regimens, as its long natural history gives time to exploit the potentially beneficial GvL effect. So far, few results of nonmyeloablative allogeneic BMT are available in FL161,187,195-200 (Table 6). Khouri et al161 first reported on 6 cases of heavily pretreated FL and 9 similar cases of CLL. Eleven of the 15 patients had durable engraftment with 50% to 100% donor cells one month following transplantation, converting to 100% over the next 2 months either spontaneously or after DLI. Hematopoietic recovery was prompt, and 8 of the 11 patients with engraftment achieved CR.161 Maximal responses were slow to develop and gradually occurred over a period of several months to one year. Subsequently, nonmyeloablative allogeneic BMT has been reported in others cases of heavily pretreated, high-risk lymphoma. Evidence for GvL activity have been observed as residual posttransplantation active disease declined with the onset of chronic GVHD161,187,197,198 or after DLI infusion.187,196,197 High doses of rituximab (375 mg/m2 on day 6 and 1000 mg/m2 on days 1, 8, and 15 after transplantation) have been administered to enhance tumor
control early after transplantation to allow time for the GvL effect to
occur.187 This improves the antitumoral activity
of the fludarabine-cyclophosphamide conditioning, as 8 of 8 patients in
partial response before transplantation achieved CR, 2 of them
concomitant with the withdrawal of tacrolimus and subsequent
development of GVHD. At a median follow-up of 21 months, 84% of
patients are still in CR despite advance recurrent disease. The low TRM allows to perform nonmyeloablative allogenic PSCT after ABMT conditioned by BEAM therapy.196 The high
response rate (9 patients in partial remission after
autologous grafting achieved CR after mini-allografting) in this group
of heavily pretreated patients is promising. However, acute and chronic
GVHD continue to be a problem,195-200 and
controlled prospective trials are warranted to assess if
nonmyeloablative alloBMT can indeed improve outcomes of patients with
FL.
There is not yet a clear demonstration that HDT followed by ASCT improves the OS of patients when used as first-line treatment. However, the results of several trials will soon allow determination of its role. For patients with chemoresistant disease, allogeneic SCT must be considered if patients have an HLA-identical sibling. Conventional allogeneic SCT is probably the best procedure for patients younger than 50 years. For older patients, nonmyeloablative treatment probably yields a similar cure rate with a lower TRM. For patients who relapse with disseminated disease after a complete or partial response, salvage chemotherapy followed by autologous SCT improves response rate, survival from second relapse, and probably overall survival compared with conventional therapy. Although there is no clear demonstration that stem cell harvest purging decreases the relapse rate and improves survival, in vivo treatment by anti-B monoclonal antibodies such as rituximab are an attractive option, because they have both an antilymphoma and a purging effect on blood and BM. These results must be confirmed by ongoing clinical trials. Despite these improvements, many patients still relapse, and additional therapies must be tested. Posttransplantation immunotherapy is a promising approach.
Submitted July 27, 2001; accepted April 20, 2002.
Reprints: Philippe Solal-Celigny, Centre Jean Bernard, 9 rue Beauverger 72 000 Le Mans, France; e-mail: p.solal-celigny{at}noos.fr.
1.
Horning SJ.
Follicular lymphoma: have we made any progress?
Ann Oncol.
2000;11:23-27
2.
Johnson PW, Rohatiner AZ, Whelan JS, et al.
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
J Clin Oncol.
1995;13:140-147 3. Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol. 2000;65:17-22[CrossRef][Medline] [Order article via Infotrieve]. 4. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 2000;25:957-964[CrossRef][Medline] [Order article via Infotrieve].
5.
Apostolidis J, Gupta RK, Grenzelias D, et al.
High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up.
J Clin Oncol.
2000;18:527-536
6.
Freedman AS, Neuberg D, Mauch P, et al.
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.
Blood.
1999;94:3325-3333 7. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:383-389[CrossRef][Medline] [Order article via Infotrieve].
8.
Brice P, Simon D, Bouabdallah R, et al.
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.
Ann Oncol.
2000;11:1585-1590 9. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma. 1999;34:129-136[Medline] [Order article via Infotrieve].
10.
Verdonck L, Dekker A, Lokhorst H, Petersen E, Nieuwenhuis H.
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
Blood.
1997;90:4201-4205
11.
Bastion Y, Brice P, Haioun C, et al.
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Blood.
1995;86:3257-3262 12. Colombat P, Donadio D, Fouillard L, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant. 1994;13:157-162[Medline] [Order article via Infotrieve].
13.
Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO.
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.
J Clin Oncol.
1997;15:445-450 14. Molina A, Nademanee A, O'Donnell M, et al. Long-term follow-up and analysis of prognostic factors after high-dose therapy and peripheral blood stem cell autografting in 58 patients with a history of low grade follicular lymphoma [abstract]. Blood. 1999;94:171a. 15. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant. 2001;7:294-301[CrossRef][Medline] [Order article via Infotrieve]. 16. Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol. 2001;80:398-405[CrossRef][Medline] [Order article via Infotrieve]. 17. Lopez R, Martino R, Sureda A, et al. Autologous stem cell transplantation in advanced follicular lymphoma: a single center experience. Haematologica. 1999;84:350-355. 18. Schouten H, Kvaloy S, Sydes M, Qian W, Fayers P. The CUP trial: a randomized study analysing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma. Ann Oncol. 2000;11(suppl 1):S91-S94.
19.
Fouillard L, Laporte JP, Labopin M, et al.
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation 20. Cervantes F, Shu XO, McGlave PB, et al. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1995;16:387-392[Medline] [Order article via Infotrieve].
21.
Rohatiner A, Johnson P, Price C, et al.
Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.
J Clin Oncol.
1994;12:1177-1184
22.
Schouten HC, Bierman PJ, Vaughan WP, et al.
Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation.
Blood.
1989;74:2579-2584 23. Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999;5:262-268[CrossRef][Medline] [Order article via Infotrieve].
24.
Foran JM, Apostolidis J, Papamichael D, et al.
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre.
Ann Oncol.
1998;9:865-869
25.
Williams CD, Harrison CN, Lister TA, et al.
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
J Clin Oncol.
2001;19:727-735 26. Belanger C, Simon D, Brice P, et al. Incidence of histological transformation at first relapse in follicular lymphoma patients included in the prospective GELF 86 protocol [abstract]. Ann Oncol. 1999;10(suppl 3):216a. 27. Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol. 2001;113:202-208[CrossRef][Medline] [Order article via Infotrieve]. 28. Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726-1733[Medline] [Order article via Infotrieve]. 29. Moos M, Schulz R, Martin S, Benner A, Haas R. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia. 1998;12:1971-1976[CrossRef][Medline] [Order article via Infotrieve].
30.
Gribben JG, Neuberg D, Freedman AS, et al.
Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.
Blood.
1993;81:3449-3457 31. Corradini P, Ladetto M, Astolfi M, et al. Long-term molecular follow-up in indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: durable molecular and clinical remission can be achieved only in follicular subtypes [abstract]. Blood. 2001;98:681a. 32. Johnson P, Price C, Smith T, et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol. 1994;12:798-805[Abstract].
33.
Heid CA, Stevens J, Livak KJ, Williams PM.
Real time quantitative PCR.
Genome Res.
1996;6:986-994 34. Hirt C, Dolken G. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant. 2000;25:419-426[CrossRef][Medline] [Order article via Infotrieve].
35.
Zwicky C, Maddocks A, Andersen N, Gribben J.
Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
Blood.
1996;88:3314-3322 36. Salles G, Coiffier B. Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol. 1999;12:151-169[Medline] [Order article via Infotrieve]. 37. Tarella C, Caracciolo D, Corradini P, et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated up front with high-dose sequential chemotherapy and autograft. Leukemia. 2000;14:740-747[CrossRef][Medline] [Order article via Infotrieve]. 38. Morel P, Laporte JP, Noel MP, et al. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia. 1995;9:576-582[Medline] [Order article via Infotrieve].
39.
Horning SJ, Negrin RS, Hoppe RT, et al.
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
Blood.
2001;97:404-409
40.
Freedman AS, Gribben JG, Neuberg D, et al.
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
Blood.
1996;88:2780-2786 41. Bociek R, Bierman P, Vose J, Lynch J, Morris M, Armitage J. High dose therapy with autologous hematopoietic stem cell transplantation for patients with low-grade follicular non-Hodgkin's lymphoma in first complete or partial remission [abstract]. Blood. 1999;94:170a. 42. Colombat P, Cornillet P, Deconinck E, et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant. 2000;26:971-977[CrossRef][Medline] [Order article via Infotrieve]. 43. Gonzalez-Barca E, Fernandez de Sevilla A, Domingo-Claros A, et al. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant. 2000;26:1051-1056[CrossRef][Medline] [Order article via Infotrieve]. 44. Ladetto M, Corradini P, Sametti S, et al. The GITMO experience with high-dose chemotherapy and autografting in advanced follicle center lymphoma: a multicenter trial showing good feasibility and frequent achievement of clinical and molecular remission [abstract]. Blood. 2001;98:678a. 45. Sanz-Rodriguez C, Sanchez A, Rodriguez F, Gandarillas M, Conde E, Arranz R. Chemotherapy plus interferon alpha-2b vs high-dose therapy for response consolidation in low grade non-Hodgkin's lymphoma: results of a retrospective case control study [abstract]. Blood. 2000;96:791a. 46. Hiddemann W, Unterhalt M, Wandt H, et al. Myeloablative radiochemotherapy followed by blood stem cell transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized comparison by the German Low-Grade Lymphoma Study Group [abstract]. Blood. 1999;96:610a. 47. Colombat P, Foussard C, Bertrand P, et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: first results of the randomized GOELAMS 064 trial [abstract]. Blood. 2001;98:861a. 48. Romaguera JE. Can we identify patients with low grade lymphoma for frontline ABMT? Leuk Lymphoma. 1993;10:9-15[Medline] [Order article via Infotrieve]. 49. Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone A. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data: Lymphoma Working Party of the EBMT. Ann Oncol. 1994;5(suppl 2):151-153[Medline] [Order article via Infotrieve].
50.
Majolino I, Pearce R, Taghipour G, Goldstone AH.
Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data: Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol.
1997;15:509-517 51. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353-357[CrossRef][Medline] [Order article via Infotrieve]. 52. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995;13:1328-1335[Abstract].
53.
Hartmann O, Le Corroller AG, Blaise D, et al.
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs: a randomized, controlled trial.
Ann Intern Med.
1997;126:600-607
54.
Leonard BM, Hetu F, Busque L, et al.
Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
Blood.
1998;91:331-339 55. Kanteti R, Miller K, McCann J, et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant. 1999;24:473-481[CrossRef][Medline] [Order article via Infotrieve]. 56. Talmadge JE, Reed E, Ino K, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 1997;19:161-172[CrossRef][Medline] [Order article via Infotrieve].
57.
Pettengell R, Morgenstern GR, Woll PJ, et al.
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Blood.
1993;82:3770-3777
58.
To LB, Haylock DN, Simmons PJ, Juttner CA.
The biology and clinical uses of blood stem cells.
Blood.
1997;89:2233-2258 59. Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;100:338-347[CrossRef][Medline] [Order article via Infotrieve]. 60. Kroger N, Zeller W, Fehse N, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol. 1998;102:1101-1106[CrossRef][Medline] [Order article via Infotrieve]. 61. Kessinger A, Bierman P, Cowles M, et al. Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade non-Hodgkin lymphoma. Can Res Therapy Control. 1998;5:113-119.
62.
Facon T, Harousseau JL, Maloisel F, et al.
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Blood.
1999;94:1218-1225 63. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant. 1999;23(suppl 2):S29-S33[Medline] [Order article via Infotrieve]. 64. Bashford J, Durrant S, Schwarer A, et al. Ancestim (r-metHuSCF) plus filgrastim (r-metHuG-CSF) allows mobilization of peripheral blood stem cells for transplantation in patients failing mobilization with filgrastim alone [abstract]. Blood. 2000;96:178a. 65. Azar N, Vantelon J, Hasmati P, et al. Ancestim (r-metHuSCF): mobilization of peripheral blood stem cells (PBSC) in patients with prior unsuccessful mobilization with G-CSF: experience of 67 cases of compassionate use in France [abstract]. Blood. 2000;96:178a.
66.
Haas R, Mohle R, Fruhauf S, et al.
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.
Blood.
1994;83:3787-3794 67. Haas R, Moos M, Mohle R, et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1996;17:149-155[Medline] [Order article via Infotrieve]. 68. Perry A, Watts M, Peniket A, Goldstone A, Linch D. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant. 1998;12:1201-1205.
69.
McQuaker I, Haynes A, Anderson S, et al.
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.
J Clin Oncol.
1997;15:2288-2295 70. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547-2555[Abstract]. 71. Vantelon JM, Koscielny S, Brault P, et al. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant. 2000;25:495-499[CrossRef][Medline] [Order article via Infotrieve]. 72. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant. 1992;9:11-17[Medline] [Order article via Infotrieve]. 73. O'Donnell P, Loper K, Flinn I, Vogelsang G, Grever M, Noga S. Effect of fludarabine chemotherapy on peripheral blood stem cell transplantation [abstract]. Blood. 1998;92:120a. 74. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma. 2000;37:157-161[Medline] [Order article via Infotrieve]. 75. Micallef I, Apostolidis J, Rohatiner A, et al. Factors which predict unsuccessful mobilization of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematology J. 2000;1:367-373.
76.
Gribben J, Freedman A, Woo S, et al.
All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
Blood.
1991;78:3275-3280 77. Sharp J, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol. 1996;14:214-219[Abstract]. 78. Bachier CR, Giles RE, Ellerson D, et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32:279-288[Medline] [Order article via Infotrieve]. 79. Brenner M, Rill D, Moen R, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85-86[CrossRef][Medline] [Order article via Infotrieve]. 80. Gribben J, Freedman A, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533[Abstract]. 81. Martin-Henao GA, Picon M, Limon A, et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Bone Marrow Transplant. 1999;23:579-587[CrossRef][Medline] [Order article via Infotrieve].
82.
Gribben J, Saporito L, Barber M, et al.
Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.
Blood.
1992;80:1083-1089
83.
Negrin RS, Pesando J.
Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
J Clin Oncol.
1994;12:1021-1027 84. Pappa VI, Wilkes S, Salam A, Young BD, Lister TA, Rohatiner AZ. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment. Bone Marrow Transplant. 1998;22:553-558[CrossRef][Medline] [Order article via Infotrieve].
85.
Corradini P, Astolfi M, Cherasco C, et al.
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
Blood.
1997;89:724-731
86.
Gorin N, Lopez M, Laporte J, et al.
Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma.
Blood.
1995;85:1647-1654 87. Voso M, Hohaus S, Moos M, et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol. 1999;104:382-391[CrossRef][Medline] [Order article via Infotrieve]. 88. Marin G, Dal Cortivo L, Cayuela J, et al. Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma. Hematol Cell Ther. 1997;39:33-40[CrossRef][Medline] [Order article via Infotrieve].
89.
Bomberger C, Singh-Jairam M, Rodey G, et al.
Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors.
Blood.
1998;91:2588-2600 90. Divine M, Boutolleau D, Delfau-Larue MH, et al. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol. 1999;105:349-360[CrossRef][Medline] [Order article via Infotrieve].
91.
Macintyre E, Belanger C, Debert C, et al.
Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients.
Blood.
1995;86:4691-4698 92. Paulus U, Schmitz N, Viehmann K, von Neuhoff N, Dreger P. Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant. 1997;20:415-420[CrossRef][Medline] [Order article via Infotrieve]. 93. Yao M, Fouillard L, Lemoine FM, et al. Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: no evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells. Bone Marrow Transplant. 2000;26:497-503[CrossRef][Medline] [Order article via Infotrieve]. 94. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM. Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34-positive cells. Lancet. 1999;354:1092-1093[CrossRef][Medline] [Order article via Infotrieve]. 95. McNiece I, Briddell R. Ex vivo expansion of hematopoietic progenitor cells and mature cells. Exp Hematol. 2001;29:3-11[Medline] [Order article via Infotrieve].
96.
Widmer L, Pichert G, Jost L, Stahel R.
Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Blood.
1996;88:3166-3175
97.
Magni M, Di Nicola M, Devizzi L, et al.
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
Blood.
2000;96:864-869 98. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol. 2000;109:729-735[CrossRef][Medline] [Order article via Infotrieve]. 99. Haioun C, Delfau-Larue M, Beaujean F, et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study [abstract]. Blood. 2000;96:184a. 100. Buckstein R, Imrie K, Spaner D, et al. Autologous stem cell transplants combined with rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions [abstract]. Blood. 2001;98:680a. 101. Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by in vivo purging with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol. 1999;26:115-122[Medline] [Order article via Infotrieve]. 102. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6:628-632[CrossRef][Medline] [Order article via Infotrieve]. 103. Blystad A, Kvaloy S, Delabie J, et al. High-dose therapy in high-grade non-Hodgkin's lymphoma patients: comparison between unmanipulated peripheral blood progenitor cells and purged autologous bone marrow as stem cell support [abstract]. Blood. 2000;96:183a. 104. Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;38:91-101[Medline] [Order article via Infotrieve]. 105. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997;3:98-106[Medline] [Order article via Infotrieve]. 106. Johnson RE, Canellos GP, Young RC, Chabner BA, DeVita VT. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep. 1978;62:321-325[Medline] [Order article via Infotrieve].
107.
Girinsky T, Benhamou E, Bourhis JH, et al.
Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies.
J Clin Oncol.
2000;18:981-986 108. Stein RS, Greer JP, Goodman S, et al. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;25:257-262[CrossRef][Medline] [Order article via Infotrieve]. 109. Williams C, Goldstone A, Pearce R, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol. 1996;14:2454-2564[Abstract]. 110. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996;2:76-85[Medline] [Order article via Infotrieve].
111.
Press OW, Eary JF, Gooley T, et al.
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
Blood.
2000;96:2934-2942 112. Behr TM, Wormann B, Gramatzki M, et al. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res. 1999;5:3304s-3314s[Medline] [Order article via Infotrieve]. 113. Hardingham J, Kotasek D, Sage R, et al. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:1073-1079[Abstract].
114.
Guillaume T, Rubinstein DB, Symann M.
Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.
Blood.
1998;92:1471-1490 115. Guillaume T, Rubinstein DB, Symann M. Immunological recovery and tumour-specific immunotherapeutic approaches to post-autologous haematopoietc stem cell transplantation. Baillières Clin Haematol. 1999;12:293-306.
116.
Grossbard ML, Multani PS, Freedman AS, et al.
A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Clin Cancer Res.
1999;5:2392-2398 117. Horwitz S, Breslin S, Negrin R, et al. Adjuvant rituximab after autologous peripheral blood stem cell transplant results in delayed immune reconstitution without increase in infectious complications [abstract]. Blood. 2000;96:384a. 118. Slavin S, Nagler A. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol. 1998;9:S31-S39. 119. Slavin S, Nagler A. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants. Cancer J Sci Am. 1997;3(suppl 1):S59-S67[Medline] [Order article via Infotrieve]. 120. Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1994;13:311-316[Medline] [Order article via Infotrieve]. 121. Vey N, Blaise D, Tiberghien P, et al. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leuk Lymphoma. 1996;21:107-114[Medline] [Order article via Infotrieve].
122.
Klingemann HG, Grigg AP, Wilkie-Boyd K, et al.
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse.
Blood.
1991;78:3306-3311 123. Fierro MT, Liao XS, Lusso P, et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia. 1988;2:50-54[Medline] [Order article via Infotrieve].
124.
Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S.
Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.
Blood.
1997;89:3951-3959 125. Baron F, Gothot A, Salmon JP, et al. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol. 2000;111:745-753[CrossRef][Medline] [Order article via Infotrieve].
126.
Hess A, Bright E, Thoburn C, Vogelsang G, Jones R, Kennedy M.
Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide.
Blood.
1997;89:2203-2209 127. Gryn J, Johnson E, Goldman N, et al. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant. 1997;19:221-226[CrossRef][Medline] [Order article via Infotrieve]. 128. Kwak L, Campbell M, Czerwinski D, Hart S, Miller R, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215[Abstract].
129.
Davis T, Maloney D, Czerwinski D, Liles T, Levy R.
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
Blood.
1998;92:1184-1190
130.
Hsu FJ, Caspar CB, Czerwinski D, et al.
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma 131. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177[CrossRef][Medline] [Order article via Infotrieve]. 132. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998;4:1281-1286[CrossRef][Medline] [Order article via Infotrieve]. 133. Hart DN, Hill GR. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol. 1999;77:451-459[CrossRef][Medline] [Order article via Infotrieve]. 134. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58[CrossRef][Medline] [Order article via Infotrieve]. 135. Bendandi M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia. 2000;14:1333-1339[CrossRef][Medline] [Order article via Infotrieve]. 136. Davis TA, Hsu FJ, Caspar CB, et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant. 2001;7:517-522[CrossRef][Medline] [Order article via Infotrieve].
137.
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI.
Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
Blood.
2000;95:3011-3019
138.
Apostolidis J, Foran JM, Johnson PW, et al.
Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma.
J Clin Oncol.
1999;17:216-221 139. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833[Abstract].
140.
Kaminski MS, Estes J, Zasadny KR, et al.
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Blood.
2000;96:1259-1266
141.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH.
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.
Blood.
2000;95:3273-3279
142.
Stone RM, Neuberg D, Soiffer R, et al.
Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
J Clin Oncol.
1994;12:2535-2542
143.
Bhatia S, Ramsay NK, Steinbuch M, et al.
Malignant neoplasms following bone marrow transplantation.
Blood.
1996;87:3633-3639
144.
Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ.
Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy.
Blood.
1994;83:3780-3786
145.
Darrington DL, Vose JM, Anderson JR, et al.
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
J Clin Oncol.
1994;12:2527-2534
146.
Anderson JR, Vose J, Kessinger A.
Myelodysplastic syndrome after autologous transplant for lymphoma.
Blood.
1994;84:3988-3989 147. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT: EBMT Lymphoma and Late Effects Working Parties, European Group for Blood and Marrow Transplantation. Br J Haematol. 1999;106:1020-1026[CrossRef][Medline] [Order article via Infotrieve].
148.
Friedberg JW, Neuberg D, Stone RM, et al.
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.
J Clin Oncol.
1999;17:3128-3135
149.
Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ.
Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
Blood.
1994;84:957-963
150.
Micallef IN, Lillington DM, Apostolidis J, et al.
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.
J Clin Oncol.
2000;18:947-955
151.
Krishnan A, Bhatia S, Slovak ML, et al.
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Blood.
2000;95:1588-1593
152.
Lillington DM, Micallef IN, Carpenter E, et al.
Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.
J Clin Oncol.
2001;19:2472-2481 153. Horning S, Cherry A, Bangs D, Negrin R, Blume K. Serial assessment of marrow cytogenetics after autologous transplantation of follicular lymphoma [abstract]. Blood. 2000;96:406a. 154. van Besien K, Khouri I, Giralt S, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995;13:1096-1102[Abstract].
155.
van Besien K, Sobocinski K, Rowlings P, et al.
Allogeneic bone marrow transplantation for low-grade lymphoma.
Blood.
1998;92:1832-1836 156. Mandigers C, Raemaekers J, Schattenberg A, et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol. 1998;100:198-206[CrossRef][Medline] [Order article via Infotrieve]. 157. Stein R, Greer J, Goodman S, Kallianpur A, Ahmed M, Wolff S. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant. 1999;23:227-233[CrossRef][Medline] [Order article via Infotrieve]. 158. Toze CL, Shepherd JD, Connors JM, et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25:605-612[CrossRef][Medline] [Order article via Infotrieve]. 159. Forrest D, Matheson K, Couban S, Nevill T, Fernandez L. High-dose therapy and allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma [abstract]. Blood. 2001;98:408a. 160. Cull GM, Haynes AP, Byrne JL, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol. 2000;108:754-760[CrossRef][Medline] [Order article via Infotrieve]. 161. Khouri I, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824[Abstract]. 162. Berdeja JG, Jones RJ, Zahurak ML, et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant. 2001;7:561-567[CrossRef][Medline] [Order article via Infotrieve]. 163. Mitterbauer M, Neumeister P, Kalhs P, et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia. 2001;15:635-641[CrossRef][Medline] [Order article via Infotrieve].
164.
Chopra R, Goldstone AH, Pearce R, et al.
Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data.
J Clin Oncol.
1992;10:1690-1695 165. van Besien K, de Lima M, Giralt S, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:977-982[CrossRef][Medline] [Order article via Infotrieve]. 166. Mandigers C, Meijerink J, Raemaekers J, Schattenberg A, Mensink E. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet. 1998;352:1522-1523[CrossRef][Medline] [Order article via Infotrieve].
167.
Korbling M, Anderlini P.
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Blood.
2001;98:2900-2908 168. Sharp JG, Kessinger A, Lynch JC, Pavletic ZS, Joshi SS. Blood stem cell transplantation: factors influencing cellular immunological reconstitution. J Hematother Stem Cell Res. 2000;9:971-981[CrossRef][Medline] [Order article via Infotrieve]. 169. Soiffer RJ, Freedman AS, Neuberg D, et al. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:1177-1181[CrossRef][Medline] [Order article via Infotrieve]. 170. Noga S, Seber A, Davis J, et al. CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment. J Hematother. 1998;7:151-157[Medline] [Order article via Infotrieve]. 171. Juckett M, Rowlings P, Hessner M, et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant. 1998;21:893-899[CrossRef][Medline] [Order article via Infotrieve].
172.
Mackinnon S, Papadopoulos E, Carabasi M, et al.
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Blood.
1995;86:1261-1268
173.
Soiffer R, Alyea E, Canning C, et al.
A randomized trial of CD8+ T cell depletion to prevent graft-vs-host disease associated with donor lymphocyte infusions.
Blood.
2001;98:3554-3561
174.
Bonini C, Ferrari G, Verzeletti S, et al.
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science.
1997;276:1719-1724 175. Sandmaier B, Maloney D, Gooley T, et al. Nonmyeloablative haematopoietic stem cell for HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen [abstract]. Blood. 2001;98:742a. 176. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115:653-659[CrossRef][Medline] [Order article via Infotrieve]. 177. Wasch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-250[CrossRef][Medline] [Order article via Infotrieve].
178.
Corradini P, Tarella C, Olivieri A, et al.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Blood.
2002;99:75-82 179. Raiola AM, Van Lint MT, Lamparelli T, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 2000;109:716-721[CrossRef][Medline] [Order article via Infotrieve]. 180. Alessandrino EP, Bernasconi P, Colombo AA, et al. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol. 2001;80:521-524[CrossRef][Medline] [Order article via Infotrieve].
181.
Slavin S, Nagler A, Naparstek E, et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Blood.
1998;91:756-763 182. Slavin S, Or R, Prighozina T, et al. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplant. 2000;25(suppl 2):S54-S57[Medline] [Order article via Infotrieve].
183.
Giralt S, Thall PF, Khouri I, et al.
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Blood.
2001;97:631-637
184.
Kottaridis PD, Milligan DW, Chopra R, et al.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Blood.
2000;96:2419-2425
185.
Bornhauser M, Thiede C, Platzbecker U, et al.
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Clin Cancer Res.
2001;7:2254-2262 186. Craddock C, Bardy P, Kreiter S, et al. Short Report: engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol. 2000;111:797-800[CrossRef][Medline] [Order article via Infotrieve].
187.
Khouri IF, Saliba RM, Giralt SA, et al.
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Blood.
2001;98:3595-3599
188.
Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R.
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
Blood.
2001;98:3584-3588 189. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350[CrossRef][Medline] [Order article via Infotrieve]. 190. Martino R, Caballero MD, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:341-347[CrossRef][Medline] [Order article via Infotrieve]. 191. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26:251-255[CrossRef][Medline] [Order article via Infotrieve].
192.
Chakraverty R, Peggs K, Chopra R, et al.
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Blood.
2002;99:1071-1078 193. Maris M, Niederwieser D, Sandmaier B, et al. Nonmyeloablative hematopoietic stem cell transplants using 10/10 HLA antigen matched unrelated donors for patients with advanced hematologic malignancies ineligible for conventional HSCT [abstract]. Blood. 2001;98:858a. 194. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol. 2000;28:1096-1104[CrossRef][Medline] [Order article via Infotrieve]. 195. Mohty M, Fegueux N, Exbrayat C, et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant. 2001;28:335-339[CrossRef][Medline] [Order article via Infotrieve].
196.
Carella AM, Cavaliere M, Lerma E, et al.
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
J Clin Oncol.
2000;18:3918-3924 197. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:1021-1028[CrossRef][Medline] [Order article via Infotrieve]. 198. Dreger P, Glass B, Seyfarth B, et al. Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT. Bone Marrow Transplant. 2000;26:1361-1363[CrossRef][Medline] [Order article via Infotrieve]. 199. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759[CrossRef][Medline] [Order article via Infotrieve]. 200. Hou J, Fowler D, Wilson W, et al. Potent graft-versus-lymphoma effect after nonmyeloablative stem cell transplant in refractory non-Hodgkin's lymphoma: role of rapid complete donor chimerism [abstract]. Blood. 2001;98:404a.   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Introduction
Autologous stem cell...
for example, high-dose chemotherapy (HDT) or chemoradiotherapy followed by autologous or allogeneic hematopoietic stem cell
transplantation
IFN) given after ABMT for
NHL,
